Evidence map›Paper›PMID 32776461›Full record

ArticleJournal of biomedical materials research. Part A2021

Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β.

Luman Liu, Prakash Kshirsagar, John Christiansen, Shailendra K Gautam, Abhijit Aithal, Mansi Gulati, Sushil Kumar, Joyce C Solheim, Surinder K Batra, Maneesh Jain and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical materials research. Part A, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Polyanhydride Chemistry.Biomacromolecules · 2022
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Luman LiuDepartment of Chemical and Biological Engineering, Iowa State University, Ames, Iowa, USA.
Prakash KshirsagarDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
John ChristiansenDepartment of Veterinary Microbiology and Preventative Medicine, Iowa State University, Ames, Iowa, USA.
Shailendra K GautamDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Abhijit AithalDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Mansi GulatiDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Sushil KumarDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Joyce C SolheimNanovaccine Institute, Iowa State University, Ames, Iowa, USA.
Surinder K BatraDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Maneesh JainDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Michael J WannemuehlerDepartment of Veterinary Microbiology and Preventative Medicine, Iowa State University, Ames, Iowa, USA.
Balaji NarasimhanDepartment of Chemical and Biological Engineering, Iowa State University, Ames, Iowa, USA.
University of Nebraska Medical Center · USIowa State University · USNebraska Medical Center · US

Funding

Nanovaccine platforms to combat pancreatic cancerU01CA213862 · NCI · IOWA STATE UNIVERSITY · PI JAIN, MANEESH, NARASIMHAN, BALAJI · 2017 to 2021
$2.7M
NCI NIH HHS U01 CA213862
6 · The paper itself

Abstract

Pancreatic cancer (PC) is one of the most lethal malignancies and represents an increasing and challenging threat, especially with an aging population. The identification of immunogenic PC-specific upregulated antigens and an enhanced understanding of the immunosuppressive tumor microenvironment have provided opportunities to enable the immune system to recognize cancer cells. Due to its differential upregulation and functional role in PC, the transmembrane mucin MUC4 is an attractive target for immunotherapy. In the current study we characterized the antigen stability, antigenicity and release kinetics of a MUC4β-nanovaccine to guide further optimization and, in vivo evaluation. Amphiphilic polyanhydride copolymers based on 20 mol % 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane and 80 mol % 1,6-bis(p-carboxyphenoxy)hexane were used to synthesize nanoparticles. Structurally stable MUC4β protein was released from the particles in a sustained manner and characterized by gel electrophoresis and fluorescence spectroscopy. Modest levels of protein degradation were observed upon release. The released protein was also analyzed by MUC4β-specific monoclonal antibodies using ELISA and showed no significant loss of epitope availability. Further, mice immunized with multiple formulations of combination vaccines containing MUC4β-loaded nanoparticles generated MUC4β-specific antibody responses. These results indicate that polyanhydride nanoparticles are viable MUC4β vaccine carriers, laying the foundation for evaluation of this platform for PC immunotherapy.

Indexed as

NanoparticlesAnimalsAntigens, NeoplasmCancer VaccinesDrug CarriersEpitopesHumansMiceMucin-4Pancreatic NeoplasmsPolyanhydridesAntigens, NeoplasmCancer VaccinesDrug CarriersEpitopesMUC4 protein, humanMucin-4PolyanhydridesantigenicityimmunogenicityMUC4nanoparticlepancreatic cancerpolyanhydrideprotein stability

Identifiers

PMID32776461
PMCPMC8100985
OpenAlexW3048594103

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.